Belladonin | 23852-32-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: Belladonin
• 英文别名: bis(8-methyl-8-azabicyclo[3.2.1]octan-3-yl) 4-phenyl-2,3-dihydro-1H-naphthalene-1,4-dicarboxylate
• CAS: 23852-32-6
• 化学式: C₃₄H₄₂N₂O₄
• 分子量: 542.718
• InChiKey: GERIGMSHTUAXSI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6
• 重原子数：
  40
• 可旋转键数：
  7
• 环数：
  7.0
• sp3杂化的碳原子比例：
  0.59
• 拓扑面积：
  59.1
• 氢给体数：
  0
• 氢受体数：
  6

文献信息

• Combinations of epinastine, belladonna and pseudoephedrine as new pharmaceutical formulations
  申请人：Boehringer Ingelheim International GmbH

  公开号：EP1350512A1

  公开（公告）日：2003-10-08

  The present invention relates to novel oral pharmaceutical compositions comprising as pharmaceutically active compounds a combination of an antihistaminic-effective amount of epinastine or a pharmaceutically acceptable salt thereof, an anticholinergic amount of Belladonna alkaloids (Belladonna) or a pharmaceutically acceptable salt thereof and of a decongestant-effective amount of pseudoephedrine or a pharmaceutically acceptable salt thereof. Optionally, the formulation may comprise methylephedrine (methylephrine) in a decongestant-effective amount or a pharmaceutically acceptable salt thereof. The formulation further comprises suitable pharmaceutically acceptable carriers or excipients. Another aspect of the present invention relates to methods for the preparation of these compositions and methods of using them in the treatment of allergic diseases and/or disorders. In particular the inventive composition is useful in the treatment of saisonal allergic rhinitis and saisonal allergic conjunctivitis.

  本发明涉及新型口服药物组合物，该组合物包含抗组胺有效量的依匹斯汀或其药学上可接受的盐、抗胆碱有效量的颠茄生物碱（颠茄素）或其药学上可接受的盐以及减充血有效量的伪麻黄碱或其药学上可接受的盐的组合作为药学活性化合物。可选地，制剂可包含减充血有效量的甲基麻黄碱（methylephrine）或其药学上可接受的盐。制剂还包括合适的药学上可接受的载体或赋形剂。本发明的另一个方面涉及这些组合物的制备方法和用于治疗过敏性疾病和/或紊乱的方法。本发明的组合物尤其适用于治疗季节性过敏性鼻炎和季节性过敏性结膜炎。
• Pharmaceutical formulations containing epinastine, belladonna, and pseudoephedrine
  申请人：Boehringer Ingelheim International GmbH

  公开号：US20030228359A1

  公开（公告）日：2003-12-11

  Oral pharmaceutical compositions comprising as pharmaceutically active compounds a combination of an antihistaminic-effective amount of epinastine or a pharmaceutically acceptable salt thereof, an anticholinergic amount of Belladonna alkaloids (Belladonna) or a pharmaceutically acceptable salt thereof, and of a decongestant-effective amount of pseudoephedrine or a pharmaceutically acceptable salt thereof. Optionally, the formulation includes methylephedrine (methylephrine) or a pharmaceutically acceptable salt thereof in a decongestant-effective amount. The composition further comprises suitable pharmaceutically acceptable carriers or excipients. Another aspect of the present invention relates methods of using such pharmaceutical compositions in the treatment of allergic diseases and/or disorders, in particular, seasonal allergic rhinitis and seasonal allergic conjunctivitis.

  口服药物组合物，其药用活性化合物包括抗组胺有效量的依匹斯汀或其药学上可接受的盐、抗胆碱有效量的颠茄生物碱（颠茄素）或其药学上可接受的盐、以及减充血有效量的伪麻黄碱或其药学上可接受的盐。可选地，制剂还包括减充血剂有效量的甲基麻黄碱（methylephrine）或其药学上可接受的盐。该组合物还包括合适的药学上可接受的载体或赋形剂。本发明的另一方面涉及使用此类药物组合物治疗过敏性疾病和/或紊乱的方法，特别是季节性过敏性鼻炎和季节性过敏性结膜炎。
• Pharmaceutical formulations containing combinations of epinastine, pseudoephedrine, and methylephedrine
  申请人：Hayashi Tetsuo

  公开号：US20050084527A1

  公开（公告）日：2005-04-21

  A pharmaceutical composition comprising: (a) an antihistaminically-effective amount of epinastine or a pharmaceutically acceptable salt thereof; (b) a decongestant-effective amount of pseudoephedrine or a pharmaceutically acceptable salt thereof; (c) methylephedrine or a pharmaceutically acceptable salt thereof, and (d) a pharmaceutically acceptable carrier or excipient. wherein the composition does not comprise Belladonna.

  一种药物组合物，包含：(a)抗组胺有效量的依匹斯汀或其药学上可接受的盐；(b)减充血有效量的伪麻黄碱或其药学上可接受的盐；(c)甲基麻黄碱或其药学上可接受的盐，以及(d)药学上可接受的载体或赋形剂。
• BIS-QUATERNARY AMMONIUM DERIVATIVES AS NEUROMUSCULAR RELAXANTS
  申请人：Gyermek, Laszlo

  公开号：EP1025099A1

  公开（公告）日：2000-08-09
• COMBINATIONS OF EPINASTINE, BELLADONNA AND PSEUDOEPHEDRINE AS NEW PHARMACEUTICAL FORMULATIONS
  申请人：Boehringer Ingelheim International GmbH

  公开号：EP1492532A1

  公开（公告）日：2005-01-05